J Wernz

2.9k citations

28 papers · 2.3k indexed · h-index 20

Impact in

Oncology top 2%
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in

Oncology 22
- Viral-associated cancers and disorders 10
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 3
Genetics 7
- Chronic Lymphocytic Leukemia Research 6

Co-authors: Susan E. Krown Craig E. Metroka James L. Speyer Howard S. Höchster Bruce G. Raphael Franco M. Muggia Anne Zeleniuch‐Jacquotte Milayna Subar
Journals: Journal of Clinical Oncology (12 papers)Investigational New Drugs (1 paper)JNCI Journal of the National Cancer Institute (1 paper)JAIDS Journal of Acquired Immune Deficiency Syndromes (1 paper)Annals of Internal Medicine (1 paper)
Partner nations: United States Italy Australia

In The Last Decade

J Wernz

28 papers receiving 2.2k citations

Peers

Countries citing papers authored by J Wernz

Since Specialization

Citations

This map shows the geographic impact of J Wernz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Wernz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Wernz more than expected).

Fields of papers citing papers by J Wernz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Wernz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Wernz. The network helps show where J Wernz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J Wernz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J Wernz Line = papers co-authored together J Wernz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PATIENTS WITH AIDS RELATED PULMONARY KAPOSI'S SARCOMA (PKS) TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ALONE AFTER INDUCTION WITH SYSTEMIC CHEMOTHERAPY. JAIDS Journal of Acquired Immune Deficiency Syndromes ·Asher Chanan‐Khan, K Timmert, Carolyn Wasserheit, J Wernz, Paula Klein, Franco M. Muggia	1999	5
2	Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. Journal of Clinical Oncology ·Anil Tulpule, Rex Yung, J Wernz, Byron M. Espina, A. Myers, David T. Scadden, S Cabriales, 悦哉広瀬, William D. Boswell, Xutong Li	1998	39
3	Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. PubMed ·Howard S. Höchster, Leonard Liebes, James L. Speyer, Joan Sorich, Miguel Córdova, Ruth Oratz, J Wernz, Abraham Chachoua, Ronald H. Blum, Anne Zeleniuch‐Jacquotte	1997	49
4	Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. Journal of Clinical Oncology ·A Levine, Anil Tulpule, Beverly Boynton, Lawrence D. Kaplan, Francis J. Giles, Abdul Rahman Normazuin, David T. Scadden, Donald W. Northfelt, Ivan Silverberg, J Wernz, Byron M. Espina, D. Von Hoff	1997	34
5	Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology ·Parkash S. Gill, J Wernz, David T. Scadden, Philip Cohen, Geoffrey Mukwaya, Jamie H. Von Roenn, Max Jacobs, Sanford Kempin, Ivan Silverberg, Franklin L. McCarthy, Mark U. Rarick, A. Myers, F. Shepherd, C. Sawka, Malcolm C. Pike, Michael E. Ross	1996	319
6	Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. Journal of Clinical Oncology ·Carolyn Wasserheit, Marika Otaki, Ruth Oratz, Joan Sorich, Вениамин Верещагин, H. S. Hochster, Abraham Chachoua, J Wernz, Anne Zeleniuch‐Jacquotte, Ronald H. Blum, A. Sahni	1996	73
7	Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. PubMed ·Margaret A. Fischl, Susan E. Krown, Kevin O’Boyle, Taworn Kotchai, Steven A. Miles, J Wernz, Paul A. Volberding, James G. Kahn, Jerome E. Groopman, Judith Feinberg	1993	42
8	ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. Journal of Clinical Oncology ·James L. Speyer, Achnia Azla, Anne Zeleniuch‐Jacquotte, J Wernz, Mariano Rey, Joseph J. Sanger, E Douglas Kramer, V J Ferrans, Howard S. Höchster, Marleen Meyers	1992	263
9	Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin JNCI Journal of the National Cancer Institute ·Howard S. Höchster, Leonard Liebes, Scott Wadler, Ruth Oratz, J Wernz, Michael L. Meyers, Michael D. Green, Ronald H. Blum, James L. Speyer	1992	70
10	Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. Journal of Clinical Oncology ·Uziel Beller, James L. Speyer, Nicoletta Colombo, Joan Sorich, J Wernz, Howard S. Höchster, Anne Zeleniuch‐Jacquotte, Robert F. Porges, Emma Beckman	1991	11
11	Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. Journal of Clinical Oncology ·James L. Speyer, Uziel Beller, Nicoletta Colombo, Joan Sorich, J Wernz, Howard S. Höchster, M. Mašalas, Robert F. Porges, Franco M. Muggia, Renzo Canetta	1990	65
12	A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer Cancer Treatment Reviews ·James L. Speyer, Inez Maria Leite da Silva, Joseph J. Sanger, Anne Zeleniuch‐Jacquotte, E Douglas Kramer, Mariano Rey, J Wernz, Ronald H. Blum, Howard S. Höchster, Marleen Meyers, Franco M. Muggia	1990	20
13	Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. Journal of Clinical Oncology ·Susan E. Krown, Craig E. Metroka, J Wernz	1989	339
14	Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS) Investigational New Drugs ·Abraham Chachoua, Arturo Baez L, J Wernz, Franco M. Muggia	1989	5
15	Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. Journal of Clinical Oncology ·Abraham Chachoua, Robert L. Krigel, Are Jay John b. Casicas, Brigid Rose Halling, Michael E. Speer, L Laubenstein, J Wernz, Emanuel Berman, E. Zang, Alvin E. Friedman‐Kien	1989	49
16	Phase I study of the combination of alpha-2 interferon and cisplatinum. PubMed ·Christine Walsh, G John, J Wernz, H. S. Hochster, Howard Grossberg, Abraham Chachoua, बिनोद् कार्त्तिकेयन्, Marleen Meyers, Blum Rh	1989	13
17	Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. PubMed ·Franco M. Muggia, SA Bernal, Richard Toovey, Yanan Xiao, J.P. Bergero, J Wernz, P Engstrom	1987	12
18	Doxorubicin and interferon: rationale and clinical experience. PubMed ·Drona Bandyopadhyay, Jean-Michel Belorgey, J Wernz, Daniel L. Kisner, James M. Koeller, Roger Blum, D. Von Hoff, Franco M. Muggia	1985	3
19	Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast The American Journal of Medicine ·James L. Speyer, Inez Maria Leite da Silva, Neil Dubin, Ronald H. Blum, J Wernz, Daniel F. Roses, Joseph J. Sanger, Franco M. Muggia	1985	50
20	Activity of mitolactol in cancer of the uterine cervix. PubMed ·J Klemunes, G Gouws, J Wernz, Franco M. Muggia	1984	5

About J Wernz

J Wernz is a scholar working on Oncology, Genetics, Pathology and Forensic Medicine, Virology and Biophysics, having authored 28 papers that have together received 2.3k indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (10 papers), Lymphoma Diagnosis and Treatment (9 papers), Cancer Treatment and Pharmacology (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (5 papers), Cancer therapeutics and mechanisms (3 papers), HER2/EGFR in Cancer Research (3 papers) and HIV Research and Treatment (2 papers). The work is most often cited by research in Oncology (1.6k citations), Pathology and Forensic Medicine (840 citations), Genetics (218 citations), Cardiology and Cardiovascular Medicine (398 citations) and Reproductive Medicine (143 citations). J Wernz has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Susan E. Krown, Craig E. Metroka, James L. Speyer, Howard S. Höchster, Bruce G. Raphael, Franco M. Muggia, Anne Zeleniuch‐Jacquotte, Milayna Subar, Jerome S. Burke and Riccardo Dalla‐Favera. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, JNCI Journal of the National Cancer Institute, JAIDS Journal of Acquired Immune Deficiency Syndromes and Annals of Internal Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact